COMMUNIQUÉS West-GlobeNewswire

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
27/03/2024
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET BOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage [...]
Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results
27/03/2024
2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024 Commercialization Underway with Revenue Expected in 2H 2024 for DeepView AI ® -Burn Indication in the UK On Track [...]
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
27/03/2024
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program [...]
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
27/03/2024
ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
27/03/2024
MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the [...]
Beacon Behavioral Partners Expands to Florida with the Addition of The Neuropsychiatry & TMS Group
27/03/2024
The network of physician-driven psychiatric practices continues to expand across the Southeastern United States to enhance patient care BATON ROUGE, La., March 27, 2024 (GLOBE NEWSWIRE) -- Beacon Behavioral Partners , a [...]
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
27/03/2024
NEW YORK, NY, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Applied UV, Inc. (NASDAQ: AUVI; AUVIP) (“Applied UV” or the “Company”), a leader in smart building technology solutions, today announced that it has [...]
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version
27/03/2024
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR [...]
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
27/03/2024
Financial highlights €18.7 million available cash as of December 31 st , 2023, not including the upcoming $48 million payment as part of the recent collaboration and license partnership (February 2024) with AbbVie 1 , [...]
OSE Immunotherapeutics publie ses résultats financiers annuels 2023 et fait le point sur sa stratégie de développement
27/03/2024
OSE Immunotherapeutics publie ses résultats financiers annuels 2023 et fait le point sur sa stratégie de développement Principaux éléments financiers Position de trésorerie de 18,7 millions d’euros au 31 décembre 2023, [...]
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
27/03/2024
PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy [...]
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
27/03/2024
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical [...]
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
27/03/2024
Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage [...]
Synaptive Medical Receives FDA 510(k) Clearance for Near-Infrared Fluorescence Visualization, Expanding Application of Existing Robotic Exoscope
27/03/2024
Near-Infrared fluorescence now available on Modus X robotic exoscope, complementing system’s existing advanced fluorescence capabilities New Infrared fluorescence enables the use of Modus X for visualization of vessels [...]
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages
27/03/2024
IRVINE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) is pleased to report that the Bahamas Supreme Court has issued a formal Order officially putting an end [...]
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
27/03/2024
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare [...]
Indkaldelse Til Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00
27/03/2024
I henhold til vedtægternes pkt. 4.5 indkaldes hermed til ordinær generalforsamling i Orphazyme A/S til afholdelse den 18. april 2024 kl. 15:00 på selskabets adresse hos Visionhouse, Lyskær 8A, 2730 Herlev med følgende [...]
Tevogen Bio Announces Series A-1 Preferred Stock Investment
27/03/2024
WARREN, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell [...]
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
27/03/2024
Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024 Proof of capability [...]

Pages